Notification Date: 09 June 2026 Authority: Central Drugs Standard Control Organization Government Notifies G.S.R. 477(E); Syrups Removed from Schedule K Exemptions In a significant regulatory development, the Ministry of Health and Family Welfare, Government of India, has notified the Drugs (Fifth Amendment) Rules, 2026 vide G.S.R. 477(E), introducing an important change to the Drugs Rules, 1945. The amendment comes into force from the date of its publication in the Official Gazette. Background The draft amendment was initially published through G.S.R. 927(E) dated 29 December 2025, inviting comments and suggestions from stakeholders. Following the review of objections and recommendations received from the public and after consultation with the Drugs Technical Advisory Board (DTAB), the Central Government has finalized the amendment under the powers conferred by Sections 12 and 33 of the Drugs and Cosmetics Act, 1940. Key Amendment The notification amends Schedule K of the Drugs Rules, 1945, specifically under Serial No. 13, Item (7), by omitting the word: 'Syrups' This effectively removes syrups from the category of drugs that enjoyed exemption under the specified provisions of Schedule K. Regulatory Implications The withdrawal of exemption for syrups signifies that such products will now be required to comply with the applicable provisions of the Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945. Manufacturers, marketers, distributors, and retail channels dealing with syrup formulations should carefully evaluate the impact of this amendment on their operations and ensure regulatory compliance. What Industry Stakeholders Should Do Pharmaceutical manufacturers and marketers are advised to: • Review their product portfolio to identify syrup formulations affected by the amendment. • Assess licensing and regulatory requirements applicable to these products. • Update quality, manufacturing, and distribution practices, wherever necessary. • Ensure continued compliance with the Drugs and Cosmetics Act, 1940 and Rules made thereunder. • Seek regulatory guidance for smooth transition and implementation. Conclusion The Drugs (Fifth Amendment) Rules, 2026 (G.S.R. 477(E)) represent another step towards strengthening regulatory oversight and ensuring better control over pharmaceutical products. Stakeholders should proactively understand the implications of this amendment and take necessary measures to maintain compliance. #G.S.R. 477(E) , # Drugs (Fifth Amendment) Rules 2026 , #Schedule K Amendment 2026 , #Syrups removed from Schedule K, #Drugs Rules 1945 Amendment , #Pharmaceutical Regulatory Updates India , # CDSCO Notification 2026 , # Drugs and Cosmetics Act 1940 , #Regulatory Compliance for Syrups , #Pharma Regulatory News India
We hate spam too.
